Featured series 
Health
New AI tool can predict melanoma recurrence
May help identify which patients would benefit from aggressive treatment even at early stages of disease
Most patients with early stage melanoma are treated with surgery to remove cancerous cells (pictured).
Credit: National Cancer Institute
Most deaths from melanoma — the most lethal form of skin cancer — occur in patients who were initially diagnosed with early stage melanoma and then later experienced a recurrence, which typically goes undetected until it has spread or metastasized.
A team led by investigators at Massachusetts General Hospital recently developed an artificial intelligence-based method to predict which patients are most likely to experience a recurrence and are therefore expected to benefit from aggressive treatment. The method was validated in a study published in npj Precision Oncology.
Most patients with early stage melanoma are treated with surgery to remove cancerous cells, but patients with more advanced cancer often receive immune checkpoint inhibitors, which effectively strengthen the immune response against tumor cells but also carry significant side effects.
“There is an urgent need to develop predictive tools to assist in the selection of high-risk patients for whom the benefits of immune checkpoint inhibitors would justify the high rate of morbid and potentially fatal immunologic adverse events observed with this therapeutic class,” says senior author Yevgeniy R. Semenov, an investigator in the Department of Dermatology at MGH.
“Reliable prediction of melanoma recurrence can enable more precise treatment selection for immunotherapy, reduce progression to metastatic disease, and improve melanoma survival while minimizing exposure to treatment toxicities.”
To help achieve this, Semenov and his colleagues assessed the effectiveness of algorithms based on machine learning, a branch of artificial intelligence, that used data from patient electronic health records to predict melanoma recurrence.
Specifically, the team collected 1,720 early stage melanomas — 1,172 from the Mass General Brigham health care system and 548 from the Dana-Farber Cancer Institute — and extracted 36 clinical and pathologic features of these cancers from electronic health records to predict patients’ recurrence risk with machine learning algorithms. Algorithms were developed and validated with various MGB and DFCI patient sets, and tumor thickness and rate of cancer cell division were identified as the most predictive features.
“Our comprehensive risk prediction platform using novel machine learning approaches to determine the risk of early stage melanoma recurrence reached high levels of classification and time to event prediction accuracy,” says Semenov. “Our results suggest that machine learning algorithms can extract predictive signals from clinicopathologic features for early stage melanoma recurrence prediction, which will enable the identification of patients who may benefit from adjuvant immunotherapy.”
Additional Mass General co-authors include Ahmad Rajeh, Michael R. Collier, Min Seok Choi, Munachimso Amadife, Kimberly Tang, Shijia Zhang, Jordan Phillips, Nora A. Alexander, Yining Hua, Wenxin Chen, Diane, Ho, Stacey Duey, and Genevieve M. Boland.
This work was supported by the Melanoma Research Alliance, the National Institutes of Health, the Department of Defense, and the Dermatology Foundation.
